ITI-333

ITI-333
Identifiers
IUPAC name
  • (6bR,10aS)-8-[3-(4-fluorophenoxy)propyl]-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one
CAS Number
PubChem CID
Chemical and physical data
FormulaC22H24FN3O
Molar mass365.452 g·mol−1
3D model (JSmol)
SMILES
  • C1CN(C[C@@H]2[C@H]1N3CC(=O)NC4=CC=CC2=C43)CCCOC5=CC=C(C=C5)F
InChI
  • InChI=1S/C22H24FN3O2/c23-15-5-7-16(8-6-15)28-12-2-10-25-11-9-20-18(13-25)17-3-1-4-19-22(17)26(20)14-21(27)24-19/h1,3-8,18,20H,2,9-14H2,(H,24,27)/t18-,20-/m0/s1
  • Key:MXIJXDUPULMKIE-ICSRJNTNSA-N

ITI-333 is a drug which has a mixed mechanism of action, acting as an antagonist at the 5-HT2A, D1 and α1A receptors, and also as a partial agonist at the μ-opioid receptor.[1] In animal studies it blocked the head-twitch response produced by DOI and also reduced responses to morphine, while also reducing the symptoms produced by naloxone-precipitated withdrawal in opioid habituated mice. It has been developed for potential uses in treatment of opioid withdrawal and opioid use disorder.[2][3]

See also

References

  1. ↑ "ITI 333". AdisInsight. 16 April 2024. Retrieved 23 October 2024.
  2. ↑ Li P, Zhang Q, Zheng H, Qiao Y, Snyder GL, Martin T, et al. (June 2024). "Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders". Journal of Medicinal Chemistry. 67 (11): 9355–9373. doi:10.1021/acs.jmedchem.4c00480. PMC 11181336. PMID 38805667.
  3. ↑ Snyder GL, Li P, Martin T, Zhang L, Yao W, Zheng H, et al. (July 2024). "Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders". Psychopharmacology. 241 (7): 1477–1490. doi:10.1007/s00213-024-06578-w. PMC 11199232. PMID 38710856.


This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.